Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Kyntra Bio (0IL8) Share Price & Analysis

1 Followers

0IL8 Stock Chart & Stats

$3.42-$0.22(-5.99%)
At close: 4:30 PM GMT
$4$6$8Aug 17Aug 31Sep 14Sep 28Oct 12Oct 26Nov 9
Day’s Range
$3.39 - $3.99
52-Week Range
$3.39 - $10.50
Previous Close
$3.64
Volume
N/A
Average Volume (3M)
1,331
Market Cap
$14.54M
Enterprise Value
-$38.76M
Total Cash (Recent Filing)
$91.32M
Total Debt (Recent Filing)
$0
Price to Earnings (P/E)
0.1
Beta
0.47
Next Earnings
Nov 16, 2026 (Est.)
EPS Estimate
-3.55
Last Dividend Ex-Date
Mar 15, 2022
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Differentiated Clinical Platform

The combination of a CD46-targeted therapeutic and companion PET imaging agent gives Kyntra a differentiated development approach in mCRPC. If biomarker-guided patient selection is validated, this platform could support more focused trials, improve positioning, and create a durable niche beyond established PSMA-directed therapies.

Clinical Pipeline Progress

Kyntra has moved FG-3246 into a structured Phase II program with defined dosing, safety measures, enrollment targets, and interim endpoints. This provides a concrete path to value-bearing clinical data over the next several quarters and converts early efficacy signals into a more meaningful development test.

Liquidity And Liability Reduction

A cash runway extending into 2028 gives Kyntra time to advance its clinical programs without an immediately pressing financing requirement. The revised financing agreement and lower future obligations also improve liquidity planning, preserve more future royalty economics, and reduce balance-sheet pressure.

Bears Say

Severe Revenue Contraction

The sharp revenue decline indicates that Kyntra’s operating base is not currently producing dependable top-line growth. Negative quarterly revenue and declining TTM sales can restrict internal funding capacity, increase reliance on non-operating items or financing, and make future earnings more volatile.

Persistent Cash Burn

Continued operating and free-cash-flow losses show that Kyntra is consuming cash to sustain its business and development programs. Even with improved burn relative to earlier years, ongoing cash use can erode financial flexibility and eventually require partnering, asset monetization, or additional capital.

Nasdaq Listing Uncertainty

The delisting determination creates a material structural risk for Kyntra’s market access, investor visibility, and ability to use its listed shares in future financing or strategic transactions. Although the appeal temporarily preserves trading, the unresolved compliance process remains a meaningful corporate overhang.

Kyntra Bio News

0IL8 FAQ

What was Kyntra Bio’s price range in the past 12 months?
Kyntra Bio lowest share price was $3.39 and its highest was $10.50 in the past 12 months.
What is Kyntra Bio’s market cap?
Kyntra Bio’s market cap is $14.54M.
When is Kyntra Bio’s upcoming earnings report date?
Kyntra Bio’s next earnings report is estimated for Nov 16, 2026 (not yet confirmed), which is in 2 days.
How were Kyntra Bio’s earnings last quarter?
Kyntra Bio released its earnings results on Aug 13, 2026. The company reported $2.96 earnings per share for the quarter, beating the consensus estimate of -$3.184 by $6.144.
Is Kyntra Bio overvalued?
According to Wall Street analysts Kyntra Bio’s price is currently Undervalued.
Does Kyntra Bio pay dividends?
Kyntra Bio pays a dividend of $0.285 which represents an annual dividend yield of ―. See more information on Kyntra Bio dividends here
What is Kyntra Bio’s EPS estimate?
Kyntra Bio’s EPS estimate is -3.55.
How many shares outstanding does Kyntra Bio have?
Kyntra Bio has 4,049,124 shares outstanding.
What happened to Kyntra Bio’s price movement after its last earnings report?
Kyntra Bio reported an EPS of $2.96 in its last earnings report, beating expectations of -$3.184. Following the earnings report the stock price went down -1.367%.
Which hedge fund is a major shareholder of Kyntra Bio?
Hedge funds hold Kyntra Bio shares: the largest hedge-fund position in Kyntra Bio is 1,040,806,771 shares, and hedge funds decreased their holdings by 58.9K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology